GE Healthcare has completed the acquisition of Xcellerex, Inc., expanding its offering of technologies and services for the manufacture of biopharmaceuticals such as recombinant proteins, antibodies and vaccines.
 
Dr. Nigel Darby, vice president of BioTechnologies, and chief technology officer, GE Healthcare Life Sciences said, “Xcellerex’s expertise and reputation in technologies for biopharmaceutical manufacturing is a great fit with our business. GE and Xcellerex share a vision that an integrated approach, where we can help customers optimize every stage of their manufacturing process - from start to finish - has the potential to increase production flexibility and to deliver higher yields of finished product while reducing time to market. We believe that combining the skills of the two companies will bring great benefits for our customers in the industry.